Sanofi(US:SNY)2025-07-31 13:00Financial Performance - Sanofi reported Q2 2025 net sales of €10 billion, a 10.1% increase at CER [16] - Gross profit increased by 12.4% to €7.742 billion, with a gross margin of 77.5% [59] - Business EPS grew by 8.3% to €1.59, reflecting operating income growth and lower share count from buyback [59, 61] - The company refines 2025 sales guidance to high single-digit percentage growth [15, 19] Key Products & Pipeline - Dupixent sales reached €3.832 billion in Q2 2025, a 21.1% increase [16, 119] - Vaccines sales grew by 10.3%, driven by Beyfortus [16] - Pharma launches contributed €969 million to sales [21] - Ayvakit sales increased by 52.5% [43] Strategic Initiatives - Sanofi is actively redeploying capital through organic investment, BD/M&A, growing dividend, and share buyback [62] - The company completed the acquisition of Blueprint Medicines on July 17, 2025 [46, 64] - Sanofi is reducing environmental impact across the portfolio, with reductions in carbon footprint, water use, and resource depletion [50]